VEGFA and neoplasm: Bevacizumab (BEV) is an anti-vascular endothelial growth factor (VEGF) A antibody working as an angiogenesis inhibitor [9] that normalizes tumor vasculature [10], and decreases contrast-enhancing tumor volume and blood volume in lesions both in animal models [11, 12] and clinically [13–15].